Emyria Expands Perth Operations to Support Rising National Clinical Demand.
Emyria Limited (ASX: EMD) has strengthened its Perth operations as insurance-funded demand, AP approvals and therapist capacity continue to rise ahead of significant national expansion in 2026. The Company’s Perth clinics now have five authorised psychiatrists, with five more applications underway, and a trained network of 39 therapists delivering its Empax care model. With 67 reimbursed initial screenings already locked in for Q1 2026, Emyria has strong visibility over near-term activity across both community and private-hospital settings.
Clinic capacity has also expanded, with a third Perth treatment room operational and a fourth set to commence in early Q1 2026. The national rollout remains capital-efficient, supported by payers such as insurance programs and the Department of Veterans’ Affairs. Early patient treatments at the Brisbane clinic further validate Emyria’s scalable model, positioning the Company for robust clinical and operational growth throughout 2026.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to this. Read our Privacy Policy and Terms & Conditions
Emyria Expands Perth Operations to Support Rising National Clinical Demand.
Emyria Limited (ASX: EMD) has strengthened its Perth operations as insurance-funded demand, AP approvals and therapist capacity continue to rise ahead of significant national expansion in 2026. The Company’s Perth clinics now have five authorised psychiatrists, with five more applications underway, and a trained network of 39 therapists delivering its Empax care model. With 67 reimbursed initial screenings already locked in for Q1 2026, Emyria has strong visibility over near-term activity across both community and private-hospital settings.
Clinic capacity has also expanded, with a third Perth treatment room operational and a fourth set to commence in early Q1 2026. The national rollout remains capital-efficient, supported by payers such as insurance programs and the Department of Veterans’ Affairs. Early patient treatments at the Brisbane clinic further validate Emyria’s scalable model, positioning the Company for robust clinical and operational growth throughout 2026.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au